# Antimicrobial, anticancer activities and molecular docking of eco-friendly chitosan nanocapsule loaded with biosynthesized titanium nanoparticles by Aspergillus flavus

**Authors:** Nashwa El-Gazzar, Marwa Rafat, Gamal Rabie, Basel Sitohy

PMC · DOI: 10.3389/fmicb.2026.1741753 · Frontiers in Microbiology · 2026-02-11

## TL;DR

This study creates eco-friendly chitosan nanocapsules loaded with titanium nanoparticles to combat drug-resistant microbes and cancer cells.

## Contribution

The novel contribution is the development of chitosan nanocapsules containing biosynthesized titanium nanoparticles with potent antimicrobial and anticancer effects.

## Key findings

- Chitosan nanocapsules (CNCs) showed over 86.7% encapsulation efficacy and inhibited both Gram-positive and Gram-negative bacteria.
- CNCs exhibited low minimum inhibitory concentrations (MICs) against Salmonella typhimurium and Aspergillus fumigatus.
- CNCs were non-cytotoxic to normal human cells but reduced the viability of human colon and liver cancer cells.

## Abstract

Chitosan have been leveraged to create chitosan nanocapsules within a bio-based nanocarrier system, enhancing efficacy and overcoming widespread microbial resistance. To generate chitosan nanocapsules (CNCs) that act as inhibitory agents against pathogenic microbes, this study combined titanium nanoparticles (TiO2 NPs) with chitosan nanoparticles (Cs NPs).

A.flavus was used for the biosynthesis of TiO2NPs. Dynamic light scattering (DLS), zeta potential, atomic force microscopy (AFM), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and X-ray diffraction (XRD), were utilized to assess the physicochemical properties of TiO2NPs and their CNCs. These techniques clarified particle diameter, charge stability, specific surface area, surface morphology, shape, dimensional forms, and structural parameters, respectively.

The findings showed that TiO2NPs and their nanocapsules achieved an encapsulation efficacy of over 86.7 ± 1.8% at 1.5% w/v chitosan concentration, with particle sizes of 40.7, 40.6, and 87.3 nm for TiO2NPs, CsNPs, and CNCs, respectively. Nanoparticle stability was confirmed by a zeta potential greater than –30.1 ± 4.5mV for TiO2NPs. Furthermore, TiO2NPs and their nanocapsules suppressed both Gram-positive and Gram-negative bacteria, with CNCs exhibiting more potent inhibitory effects than either TiO2NPs or CsNPs. The minimum inhibitory concentrations (MICs) of CNCs against Salmonella typhimurium and Aspergillus fumigatus were remarkably low, at 20 and 10 μg mL−1, respectively. TEM images of S. typhimurium and A. fumigatus treated with CNCs exhibited asymmetric cell deformations, wrinkled external surfaces, cell depressions, and declined cell counts. Cytotoxicity studies showed that CNCs exhibited non-cytotoxic behavior on normal human melanocytes (HFB4). In contrast, CNCs reduced the viability of human colon carcinoma (HCT-116) and hepatocellular carcinoma (HepG-2).

Nanomaterials, both alone or in nanocapsules, offer a promising alternative for inhibiting harmful microorganisms and represent a potential pathway for the development of anticancer medications. The findings indicate that CNCs are safe and effective against multidrug-resistant bacteria and fungi, making them a viable alternative to current antibiotic therapies.

## Linked entities

- **Chemicals:** chitosan (PubChem CID 129662530)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256)
- **Species:** Aspergillus flavus (taxon 5059), Aspergillus fumigatus (taxon 746128), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, H1-0 (H1.0 linker histone) [NCBI Gene 3005] {aka H1.0, H10, H1F0, H1FV}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}
- **Diseases:** carcinogenesis (MESH:D063646), gastric infection (MESH:D013274), Bacterial (MESH:D001424), colon carcinoma (MESH:D003110), burn (MESH:D002056), infectious disease (MESH:D003141), thermal tissue injury (MESH:D017695), ischemia (MESH:D007511), fungal (MESH:D009181), hepatocellular carcinoma (MESH:D006528), colon cancer (MESH:D015179), Helicobacter pylori (MESH:D016481), catheter-associated infections (MESH:D055499), carcinogenic (MESH:D011230), pressure sores (MESH:D003668), diabetic ulcers (MESH:D017719), skin wounds (MESH:D014947), inflammatory (MESH:D007249), liver diseases (MESH:D008107), metabolic acidosis (MESH:D000138), wound infection (MESH:D014946), Cytotoxicity (MESH:D064420), poisoning (MESH:D011041), cancer (MESH:D009369), infection (MESH:D007239)
- **Chemicals:** TBA (MESH:C029684), OH (MESH:C031356), NYS (MESH:D009761), piperazine (MESH:D000077489), polyacrylic acid (MESH:C006903), polypropylene (MESH:D011126), penicillin G (MESH:D010400), lipopolysaccharides (MESH:D008070), sodium pyrophosphate (MESH:C003319), PMS (MESH:D008773), ABTS (MESH:C002502), Lipid (MESH:D008055), TiO2 (MESH:C009495), CO2 (MESH:D002245), Free radical (MESH:D005609), GSH (MESH:D005978), roscovitine (MESH:D000077546), itraconazole (MESH:D017964), GLN (MESH:D005973), Clindamycin (MESH:D002981), LEU (MESH:D007930), ampicillin (MESH:D000667), Cs (MESH:D002586), AMP (MESH:D000249), lanosterol (MESH:D007810), Phospholipids (MESH:D010743), fluconazole (MESH:D015725), ofloxacin (MESH:D015242), H2O. (MESH:D014867), ATP (MESH:D000255), hydroxyl (MESH:D017665), ROS (MESH:D017382), hyaluronic acid (MESH:D006820), CAS (MESH:D002118), Ethanol (MESH:D000431), polyphosphate (MESH:D011122), caspofungin (MESH:D000077336), amoxicillin (MESH:D000658), dimethyl sulfoxide (MESH:D004121), EE% (MESH:D004997), acetic acid (MESH:D019342), ascorbic acid (MESH:D001205), gentamicin (MESH:D005839), butanol (MESH:D000440), HCl (MESH:D006851), Hydrogen (MESH:D006859), PLGA (MESH:D000077182), LYS (MESH:D008239), glutaraldehyde (MESH:D005976), Acetate (MESH:D000085), potassium chloride (MESH:D011189), silver (MESH:D012834), NADH (MESH:D009243), NH3 (MESH:D000641), tetracycline (MESH:D013752), O (MESH:D010100), zinc (MESH:D015032), formazan (MESH:D005562), n-butanol (MESH:D020001), HEPES (MESH:D006531)
- **Species:** Escherichia coli ATCC 25922 (strain) [taxon 1322345], Fungi (kingdom) [taxon 4751], Salmonella enterica subsp. enterica serovar Typhimurium (no rank) [taxon 90371], A. flavus [taxon 315677], Streptococcus pyogenes (species) [taxon 1314], Aspergillus sp. (species) [taxon 5065], Escherichia coli (E. coli, species) [taxon 562], Bacillus subtilis (species) [taxon 1423], Aspergillus flavus (species) [taxon 5059], Listeria monocytogenes (species) [taxon 1639], Listeria innocua (species) [taxon 1642], Candida albicans (species) [taxon 5476], Aspergillus fumigatus (species) [taxon 746128], Enterobacter cloacae (species) [taxon 550], Homo sapiens (human, species) [taxon 9606], Klebsiella pneumoniae (species) [taxon 573], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Pseudomonas aeruginosa (species) [taxon 287], Staphylococcus aureus (species) [taxon 1280], Penicillium aurantiogriseum (species) [taxon 36655]
- **Cell lines:** HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), KF946095 — Mesocricetus auratus (Golden hamster), Hamster melanoma, Cancer cell line (CVCL_5M20), ATCC13883 — Homo sapiens (Human), Ataxia telangiectasia syndrome, Transformed cell line (CVCL_1M10), HEPG-2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), AUMC 14446 — Homo sapiens (Human), Finite cell line (CVCL_2G44), ATCC 43816 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HFB4 — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_6257)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932164/full.md

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932164/full.md

## References

80 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932164/full.md

---
Source: https://tomesphere.com/paper/PMC12932164